Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 263.38 USD 0.84% Market Closed
Market Cap: 141.6B USD
Have any thoughts about
Amgen Inc?
Write Note

Amgen Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Amgen Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Amgen Inc
NASDAQ:AMGN
Total Receivables
$7.3B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Abbvie Inc
NYSE:ABBV
Total Receivables
$11.5B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$4.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
5%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Total Receivables
$353.9m
CAGR 3-Years
36%
CAGR 5-Years
49%
CAGR 10-Years
97%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$6.1B
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Amgen Inc
Glance View

Market Cap
141.6B USD
Industry
Biotechnology
Economic Moat
Wide

Amgen Inc., a towering figure in the biopharmaceutical industry, started its journey in the early 1980s in Thousand Oaks, California, with a visionary commitment to tapping into the potential of recombinant DNA technology. This leap into biotechnology allowed the company to produce vital proteins that the body naturally lacks in certain medical conditions. Concentrating on serious illnesses such as cancer, kidney failure, and rheumatoid arthritis, Amgen transformed itself over the decades from a novel research lab into a global powerhouse, rolling out revolutionary therapies like Epogen and Neulasta. These blockbuster drugs, designed to treat anemia and prevent infections in chemotherapy patients, catapulted Amgen into the echelon of companies that not only evolve with science but also shape its trajectory. Today, Amgen thrives by blending its innovative science with strategic acquisitions, expanding its pipeline beyond merely biological drugs to include biosimilars and small molecule medicines. The company's revenue stream relies heavily on its existing successful therapies while also banking on the future with investments in genetic research and novel drug developments. By leveraging their expertise in biotechnology and clinical trials, Amgen is able to bring new products to market and navigate the complex regulatory landscape efficiently. The firm expertly balances risk and reward, ensuring a steady influx of cash flow through both established product lines and the advent of new therapies. Thus, Amgen, with its robust portfolio and strategic business maneuvers, continues to play a pivotal role in enhancing patient outcomes while reinforcing its position as a leader in the biopharmaceutical realm.

AMGN Intrinsic Value
247.23 USD
Overvaluation 6%
Intrinsic Value
Price

See Also

What is Amgen Inc's Total Receivables?
Total Receivables
7.3B USD

Based on the financial report for Sep 30, 2024, Amgen Inc's Total Receivables amounts to 7.3B USD.

What is Amgen Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
12%

Over the last year, the Total Receivables growth was 19%. The average annual Total Receivables growth rates for Amgen Inc have been 15% over the past three years , 15% over the past five years , and 12% over the past ten years .

Back to Top